Hyperspectral imaging for detection of Parkinson's disease
Described herein is the use of a visible near infrared (VNIR) hyperspectral imaging system as a non-invasive diagnostic tool for early detection of Parkinson's disease (PD). Also described herein is the use of a VNIR hyperspectral imaging system in high throughput screening of potential therapeutics against PD.
1. A method for determining whether a subject has a disorder associated with amyloidopathy and/or amyloidosis or is predisposed for developing a disorder associated with amyloidopathy and/or amyloidosis, comprising using a visible near infrared (VNIR) hyperspectral imaging system to obtain a hyperspectral image (HSI) of the retina of the subject and determining whether the HSI is indicative of the formation of amyloid aggregates, wherein the presence of said amyloid aggregates indicates the subject has a disorder associated with amyloidopathy and/or amyloidosis or is predisposed for developing a disorder associated with amyloidopathy and/or amyloidosis, wherein the wavelengths used to obtain the HSI spectrum are in the VNIR range, wherein the method is non-invasive and does not comprise administration of dyes for detection of amyloid aggregates.
2. A method for determining whether a treatment is effective in treating or preventing a disorder associated with amyloidopathy and/or amyloidosis or preventing the progress of a disorder associated with amyloidopathy and/or amyloidosis, comprising using a visible near infrared (VNIR) hyperspectral imaging system to obtain a hyperspectral image (HSI) of the retina of a subject and determining whether the treatment causes a decrease in formation of amyloid aggregates that are indicative of a disorder associated with amyloidopathy and/or amyloidosis, wherein a decrease in formation of amyloid aggregates is indicative of an effective treatment, wherein the wavelengths used to obtain the HSI spectrum are in the VNIR range, wherein the method is non-invasive and does not comprise administration of dyes for detection of amyloid aggregates.
3. The method of claim 1 , wherein the disorder associated with amyloidopathy and/or amyloidosis is cerebral amyloid angiopathy, familial amyloid polyneuropathy, Parkinson's disease, Huntington's disease, prolactinoma or a transmissible spongiform encephalopathy.
4. The method of claim 3 , wherein the disorder associated with amyloidopathy and/or amyloidosis is Parkinson's disease (PD).
5. The method of claim 4 , wherein the HSI spectrum is compared to at least a first previous HSI spectrum obtained from the subject at an earlier point in time, wherein a significant spectral difference between the HSI spectra indicates the subject has PD or is predisposed for developing PD.
6. The method of claim 4 , wherein the HSI from the subject is compared to a control reference HSI spectrum and to an PD reference HSI spectrum to determine whether the image comprises spectral differences that are indicative of PD.
7. The method of claim 4 , wherein the subject is from about 30 to 50 years old.
8. The method of claim 4 , wherein the amyloid aggregates are soluble amyloid aggregates.
9. The method of claim 4 , wherein the amyloid aggregates are insoluble amyloid aggregates.
10. The method of claim 2 , wherein the disorder associated with amyloidopathy and/or amyloidosis is cerebral amyloid angiopathy, familial amyloid polyneuropathy, Parkinson's disease, Huntington's disease, prolactinoma or a transmissible spongiform encephalopathy.
11. The method of claim 10 , wherein the disorder associated with amyloidopathy and/or amyloidosis is Parkinson's disease (PD).
12. The method of claim 11 , wherein the HSI spectrum is compared to at least a first previous HSI spectrum obtained from the subject at an earlier point in time, wherein a significant spectral difference between the HSI spectra indicates the subject has PD or is predisposed for developing PD.
13. The method of claim 11 , wherein the HSI from the subject is compared to a control reference HSI spectrum and to an PD reference HSI spectrum to determine whether the image comprises spectral differences that are indicative of PD.
14. The method of claim 11 , wherein the subject is from about 30 to 50 years old.
15. The method of claim 11 , wherein the amyloid aggregates are soluble amyloid aggregates.
16. The method of claim 11 , wherein the amyloid aggregates are insoluble amyloid aggregates.